These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9671106)

  • 1. Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5.
    Silver PJ; Pagani ED; Dundore RL; de Garavilla L; Bode DC; Bacon ER
    Eur J Pharmacol; 1998 May; 349(2-3):263-8. PubMed ID: 9671106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor.
    Silver PJ; Dundore RL; Bode DC; de Garavilla L; Buchholz RA; van Aller G; Hamel LT; Bacon E; Singh B; Lesher GY
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1143-9. PubMed ID: 7996419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal or nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinast.
    Silver PJ; Pagani ED; de Garavilla L; Van Aller GS; Volberg ML; Pratt PF; Buchholz RA
    Eur J Pharmacol; 1991 Jun; 199(1):141-2. PubMed ID: 1654265
    [No Abstract]   [Full Text] [Related]  

  • 4. Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo.
    De Garavilla L; Pagani ED; Buchholz RA; Dundore R; Bode DC; Volberg ML; Jackson KN; Pratt P; Silver PJ
    Eur J Pharmacol; 1996 Oct; 313(1-2):89-96. PubMed ID: 8905333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast.
    Pagani ED; VanAller GS; O'Connor B; Silver PJ
    Eur J Pharmacol; 1993 Oct; 243(2):141-7. PubMed ID: 8276063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization.
    Delpy E; le Monnier de Gouville AC
    Br J Pharmacol; 1996 Jul; 118(6):1377-84. PubMed ID: 8832060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.
    Merkel LA; Rivera LM; Perrone MH; Lappe RW
    Eur J Pharmacol; 1992 May; 216(1):29-35. PubMed ID: 1326438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats.
    Dundore RL; Clas DM; Wheeler LT; Habeeb PG; Bode DC; Buchholz RA; Silver PJ; Pagani ED
    Eur J Pharmacol; 1993 Nov; 249(3):293-7. PubMed ID: 8287916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle.
    Harris AL; Lemp BM; Bentley RG; Perrone MH; Hamel LT; Silver PJ
    J Pharmacol Exp Ther; 1989 May; 249(2):394-400. PubMed ID: 2566675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N omega-nitro-L-arginine attenuates the accumulation of aortic cyclic GMP and the hypotension produced by zaprinast.
    Dundore RL; Pratt PF; O'Connor B; Buchholz RA; Pagani ED
    Eur J Pharmacol; 1991 Jul; 200(1):83-7. PubMed ID: 1663042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582.
    Pagani ED; Dundore RL; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
    J Cardiovasc Pharmacol; 1994 Sep; 24(3):403-10. PubMed ID: 7528296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depressor and natriuretic effects of M&B 22,948, a guanosine cyclic 3',5'-monophosphate-selective phosphodiesterase inhibitor.
    McMahon EG; Palomo MA; Mehta P; Olins GM
    J Pharmacol Exp Ther; 1989 Dec; 251(3):1000-5. PubMed ID: 2557409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle.
    Park K; Moreland RB; Goldstein I; Atala A; Traish A
    Biochem Biophys Res Commun; 1998 Aug; 249(3):612-7. PubMed ID: 9731184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine.
    Souness JE; Brazdil R; Diocee BK; Jordan R
    Br J Pharmacol; 1989 Nov; 98(3):725-34. PubMed ID: 2480168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5.
    Hirose R; Okumura H; Yoshimatsu A; Irie J; Onoda Y; Nomoto Y; Takai H; Ohno T; Ichimura M
    Eur J Pharmacol; 2001 Nov; 431(1):17-24. PubMed ID: 11716838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
    Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
    Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors.
    Tang KM; Jang EK; Haslam RJ
    Eur J Pharmacol; 1994 Jun; 268(1):105-14. PubMed ID: 7925608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic effects of phosphodiesterase 5 and angiotensin-converting enzyme inhibition alone or in combination in conscious SHR.
    Gardiner SM; March JE; Kemp PA; Ballard SA; Hawkeswood E; Hughes B; Bennett T
    J Pharmacol Exp Ther; 2005 Jan; 312(1):265-71. PubMed ID: 15452190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline.
    Takase Y; Saeki T; Fujimoto M; Saito I
    J Med Chem; 1993 Nov; 36(24):3765-70. PubMed ID: 8254606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance.
    Kim D; Rybalkin SD; Pi X; Wang Y; Zhang C; Munzel T; Beavo JA; Berk BC; Yan C
    Circulation; 2001 Nov; 104(19):2338-43. PubMed ID: 11696475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.